Related by context. All words. (Click for frequent words.) 75 biochemical recurrence 73 locoregional 72 Radical prostatectomy 72 androgen deprivation 72 lymphadenectomy 71 prostate cancer CaP 71 adjuvant radiotherapy 71 pelvic lymphadenectomy 70 chemoradiotherapy 70 preoperative chemotherapy 70 radical cystectomy 70 neoadjuvant therapy 70 IV NSCLC 70 underwent resection 70 histologically confirmed 70 cytoreduction 69 undergone radical prostatectomy 69 external beam radiotherapy 69 PSA nadir 69 stage IIIb IV 69 neoadjuvant chemotherapy 69 operable breast cancer 69 radical prostatectomy 69 cystectomy 69 recurrent NSCLC 69 radical prostatectomy RP 69 prostate adenocarcinoma 69 EBRT 69 prostate cancer CRPC 69 prostate carcinoma 69 PSADT 68 PCa 68 recurrent prostate cancer 68 neoadjuvant 68 undergoing radical prostatectomy 68 PROLARIS 68 underwent radical prostatectomy 68 radical retropubic prostatectomy 68 liver resection 68 underwent surgical resection 68 malignant pleural mesothelioma 68 Adjuvant chemotherapy 68 fallopian tube carcinoma 68 differentiated thyroid 68 CIN2 + 68 cytoreductive surgery 68 pT3 68 prostate cancer PCa 68 epithelial ovarian cancer 68 localized prostate cancer 68 HNSCC 67 chemoradiation therapy 67 adjuvant radiation 67 biochemical relapse 67 renal tumors 67 postoperative chemotherapy 67 cytoreductive nephrectomy 67 pancreatic adenocarcinoma 67 radiotherapy RT 67 lymph node dissection 67 debulking surgery 67 nodal metastasis 67 preoperative PSA 67 curative resection 67 ipsilateral breast 67 medically inoperable 67 relapsed MM 67 metastatic bladder 67 HER2 positive metastatic breast 67 metastatic castration resistant 67 KRAS mutations occur 66 distant metastases 66 orchiectomy 66 metastatic gastric 66 intravesical therapy 66 F FDG PET 66 endometrial carcinoma 66 metastatic pancreatic 66 postoperative mortality 66 R0 resection 66 non squamous NSCLC 66 histological subtypes 66 peritoneal carcinomatosis 66 specific antigen PSA 66 nonmetastatic 66 prognostic variables 66 locoregional recurrence 66 metastatic renal cell carcinoma 66 recurrent metastatic 66 pCR 66 recurrent glioblastoma multiforme 66 chemotherapeutic regimens 66 urothelial carcinoma 66 transurethral resection 66 conformal radiotherapy 66 endocrine therapies 66 axillary dissection 66 adjuvant chemotherapy 66 unresectable tumors 66 NMIBC 66 preoperative staging 66 prostate cancer HRPC 66 tumor resection 66 ER CHOP 66 adjuvant tamoxifen 66 androgen suppression 66 postoperative complication 65 androgen suppression therapy 65 Cystectomy 65 #.#ng/ml 65 ErbB2 positive 65 perioperative morbidity 65 Hepatocellular Carcinoma HCC 65 metastatic renal cell 65 advanced adenomas 65 hepatic resection 65 contralateral breast 65 5-fluorouracil/leucovorin 65 radical nephrectomy 65 advanced neoplasia 65 surgical debulking 65 transplantation HCT 65 peritoneal cancer 65 metastatic androgen independent 65 sleeve lobectomy 65 deCODE ProstateCancer TM 65 Surgical resection 65 atypical hyperplasia 65 spinal metastases 65 extracapsular extension 65 taxane therapy 65 FDG-PET/CT 65 Prognostic factors 65 preoperative radiotherapy 65 endoscopic resection 65 nondiabetic patients 65 metastatic RCC 65 concurrent chemoradiation 65 relapsed ovarian cancer 65 neoadjuvant treatment 65 sentinel lymph node biopsy 65 Androgen deprivation therapy 64 hepatorenal syndrome 64 stage IIIB 64 patients undergoing CABG 64 urothelial cancer 64 underwent prostatectomy 64 adenomatous polyps 64 metastatic malignant melanoma 64 recurrent VTE 64 thoracoscopic lobectomy 64 pT2 64 resectable 64 ovarian carcinoma 64 ductal breast cancer 64 colorectal cancer liver metastases 64 superficial bladder cancer 64 TTF Therapy 64 androgen ablation 64 breast carcinoma 64 relapsing remitting MS RRMS 64 FOLFOX4 64 metastatic hormone refractory 64 CIN3 64 radiochemotherapy 64 parathyroidectomy 64 prognostic indicators 64 nephron sparing surgery 64 perioperative mortality 64 advanced adenoma 64 anthracycline taxane 64 mCRC patients 64 prostate biopsy 64 postoperative morbidity 64 Neoadjuvant 64 colorectal adenoma 64 underwent liver transplantation 64 distant metastasis 64 nodal metastases 64 chemoembolization 64 stage IIIB IV 64 coronary revascularization 64 LHRH receptor positive 64 axillary lymph node 64 tumor histology 64 NSTE ACS 64 mRCC 64 recurrent ovarian 64 angiographically 64 adjuvant therapy 64 carotid stenosis 64 metastatic GIST 64 trastuzumab Herceptin ® 64 cervical carcinoma 64 gemcitabine carboplatin 64 tumor recurrence 64 cancer mCRC 64 seminoma 64 leukemia AML 64 FDG PET 64 colorectal carcinoma 64 Coronary Artery Bypass Graft 63 undergo radical prostatectomy 63 chemoradiation 63 pancreatic resection 63 chronic hemodialysis 63 radiation therapy SBRT 63 oncologic outcomes 63 irinotecan chemotherapy 63 estramustine 63 adjuvant therapies 63 bladder carcinoma 63 imatinib therapy 63 Doxil ® 63 ischemic cardiomyopathy 63 nonmetastatic prostate cancer 63 Accelerated Partial Breast Irradiation 63 Adjuvant therapy 63 Acute Myeloid Leukaemia AML 63 lobular carcinoma 63 histological subtype 63 CTEPH 63 colorectal liver metastases 63 adrenalectomy 63 angiographic outcomes 63 gefitinib Iressa 63 total thyroidectomy 63 GnRH agonist 63 metastatic malignant 63 stereotactic radiotherapy 63 gadolinium enhanced 63 nonsmall cell lung cancer 63 transrectal ultrasound guided 63 metastatic castrate resistant 63 metastatic prostate cancer 63 seminal vesicle invasion 63 warfarin therapy 63 PCA3 scores 63 adenoma recurrence 63 Renal Cell Carcinoma RCC 63 castrate resistant prostate cancer 63 coronary stenting 63 refractory ovarian cancer 63 HER2 expression 63 cisplatin chemotherapy 63 clinicopathological features 63 carotid artery stenting CAS 63 BRCA2 mutation carriers 63 EUS FNA 63 metastatic renal 63 postoperative radiotherapy 63 refractory prostate cancer 63 antigen PSA 63 hepatocellular carcinomas 63 cervical lymph nodes 63 SLNB 63 cytotoxic therapy 63 multivariate Cox 63 nephrectomy 63 HER2 positive cancers 63 lung resection 63 Mitomycin C 63 lymph node removal 63 malignant lesions 63 metachronous 63 assessing T DM1 63 multivessel coronary artery 63 heavily pretreated patients 63 beta blocker therapy 63 T1c 63 node dissection 63 castrate resistant 62 gastric adenocarcinoma 62 antiangiogenic therapy 62 Metastatic Prostate Cancer 62 vincristine doxorubicin 62 prostate cancer AIPC 62 antithrombotic therapy 62 paclitaxel eluting stents 62 tumors GIST 62 basal cell carcinoma BCC 62 axillary node dissection 62 TRUS biopsy 62 renal cell carcinomas 62 allogeneic hematopoietic stem cell 62 advanced epithelial ovarian 62 Retreatment 62 prospectively randomized 62 node metastases 62 histologic subtype 62 symptomatic BPH 62 graft occlusion 62 palliative radiotherapy 62 bilateral oophorectomy 62 advanced hepatocellular carcinoma 62 nodal dissection 62 hepatic metastases 62 adjuvant cisplatin 62 lobectomy 62 neurologic progression 62 asymptomatic carotid stenosis 62 antiretroviral naïve 62 thyroid nodules 62 ablative therapy 62 HGPIN 62 resistant hormone refractory 62 situ LCIS 62 completely resected 62 lung resections 62 lymph node metastasis 62 hormone refractory 62 recurrent malignant glioma 62 MGd 62 endosonography 62 sustained virological response 62 undetectable PSA 62 neoplasia PIN 62 % CI #.#-#.# [003] 62 radioiodine therapy 62 T1a 62 HIV HCV coinfected 62 intact parathyroid hormone 62 LV dysfunction 62 situ CIS 62 pancreatic carcinoma 62 gemcitabine Gemzar 62 metastatic bone 62 thymoma 62 undergo prostate biopsy 62 percutaneous cryoablation 62 refractory colorectal cancer 62 invasive lobular 62 neoplasia 62 non squamous 62 recurrent GBM 62 metastatic CRPC 62 oral Hycamtin 62 galiximab 62 SUVmax 62 metastatic colorectal 62 KRAS mutation 62 trabectedin 62 HER2 overexpression 62 pancreatectomy 62 skeletal metastases 62 kidney allograft 62 epithelial ovarian 62 mediastinal lymph nodes 62 undergoing coronary angiography 62 antithymocyte globulin 62 tamoxifen therapy 62 Hormone Refractory Prostate Cancer 62 advanced metastatic prostate 62 virological response 62 dose melphalan 62 transvaginal sonography 62 castration resistant prostate cancer 62 micrometastasis 62 anthracycline containing 62 Stereotactic Body Radiation Therapy 62 liposomal amphotericin B 62 conventional angiography 62 serum PSA 62 GISTs 62 ALND 62 relapsed AML 62 cytotoxic chemotherapy 62 Pemetrexed 62 transarterial chemoembolization 62 baseline LDH 62 Hurthle cell 61 aromatase inhibitor therapy 61 FFR guided treatment 61 morphometric vertebral fractures 61 Gliadel Wafer 61 epithelial tumors 61 PegIFN RBV 61 hepatic lesions 61 nonischemic 61 liver metastasis 61 dacarbazine DTIC 61 pain palliation 61 bevacizumab Avastin ® 61 beam radiotherapy 61 sorafenib Nexavar 61 iniparib BSI 61 prednisone prednisolone 61 hormone receptor status 61 chemoresistant 61 atherothrombotic disease 61 epirubicin cyclophosphamide 61 FDG PET imaging 61 diffuse gastric 61 KRAS mutations 61 invasive aspergillosis 61 CYT# potent vascular disrupting 61 EBUS FNA 61 #F FDG PET 61 hormone refractory metastatic prostate 61 paclitaxel poliglumex 61 lymph node involvement 61 colon rectal 61 postmenopausal osteoporotic women 61 therapy IMRT 61 HER2 negative 61 gastrointestinal stromal tumor GIST 61 histopathologic diagnosis 61 colorectal neoplasia 61 ReN# therapy 61 perioperatively 61 duplex ultrasonography 61 metastatic HRPC 61 cisplatin resistant 61 preintervention 61 mCRPC 61 recurrent colorectal cancer 61 Natalizumab 61 TRUS 61 prospectively defined 61 esophagectomy 61 Flu Cy 61 taxane chemotherapy 61 ASCUS 61 postoperative pulmonary 61 goserelin 61 tumor necrosis 61 Squamous 61 transthoracic 61 pelvic lymph node dissection 61 precursor lesions 61 invasive lobular carcinoma 61 pigmented skin lesions 61 immunohistochemical staining 61 NATRECOR ® 61 Recurrence Score 61 grade gliomas 61 cervical lesions 61 dasatinib Sprycel 61 malignant lymphoma 61 directed thrombolysis 61 antibiotic regimens 61 TACE 61 papillary renal cell carcinoma 61 stage IIIA 61 dacarbazine chemotherapy 61 CR nPR 61 obstructive coronary artery 61 hepatectomy 61 Group RTOG 61 prostatectomy 61 dimensional conformal radiotherapy 61 locoregional disease 61 Bezielle 61 adjuvant hormonal therapy 61 perioperative complications 61 Mitoxantrone 61 unfractionated heparin UFH 61 refractory metastatic 61 nonfasting triglyceride levels 61 everolimus eluting stents 61 gemcitabine cisplatin 61 p# biomarker 61 mammographic density 61 parathyroid 61 ABVD 61 laparoscopic radical prostatectomy 61 multivariate analyzes 61 metastatic CRC 61 Anaplastic 61 previously untreated follicular 61 asymptomatic metastatic 61 smoldering myeloma 61 adnexal mass 61 virologic response 61 postoperative AF 61 surgically resectable 61 MIRP 61 PSMA ADC 61 prostate TURP 61 catheter angiography 61 proliferative retinopathy 61 ICD implantation 61 hyperplasia BPH 61 localized renal 61 Subgroup analysis 61 SHPT 61 retrospectively analyzed 61 mycophenolate mofetil 61 gemcitabine chemotherapy 61 binary restenosis 61 Radiofrequency ablation 61 grade cervical intraepithelial 61 standard chemotherapy regimens 61 FDG uptake 61 graft dysfunction 61 TURBT 61 paclitaxel carboplatin 61 ximelagatran 61 Stereotactic body 61 BRAF V#E mutation 61 axillary lymph nodes 61 CYPHER Stent 61 pneumonectomy 61 Gastrointestinal Stromal Tumors 61 nonmelanoma skin cancers 61 Medullary thyroid cancer 61 malignant pleural mesothelioma MPM 61 Platinol ® cisplatin 61 metastatic lesions 61 percutaneous vertebroplasty 61 endometrial cancers 61 RECIST Response Evaluation Criteria 61 HoLEP 61 nonobstructive CAD 61 unresectable 61 percutaneous biopsy 61 ductal adenocarcinoma 61 serum phosphate 61 ductal carcinomas 61 prospective multicenter study 60 lung metastasis 60 STRIDE PD 60 Zevalin consolidation 60 metastatic kidney 60 oral clodronate 60 Belldegrun 60 Cholangiocarcinoma 60 relapsed SCLC 60 ipsilateral stroke 60 platinum refractory 60 hemodialysis patients 60 heavily pretreated 60 myocardial viability 60 FOLFIRI alone 60 thromboembolic complications 60 CVD mortality 60 MitraClip device 60 sentinel node biopsy 60 Prostate specific antigen 60 Response Evaluation Criteria 60 polyp recurrence 60 tuberous sclerosis TS 60 laser photocoagulation 60 urine cytology 60 letrozole Femara 60 colorectal cancer CRC 60 MAGE A3 ASCI 60 serum calcium levels 60 breast pancreatic 60 cytologic 60 colorectal metastases 60 MiCK assay 60 intratumoral 60 coronary artery stenosis 60 smoldering multiple myeloma 60 pelvic radiotherapy 60 tumor subtypes 60 BEACOPP 60 liver transplant recipients 60 mutated K ras 60 temozolomide TMZ 60 progression TTP 60 NovoTTF 60 response pCR 60 esophagogastric 60 docetaxel chemotherapy 60 revascularization procedures 60 VATS lobectomy 60 sipuleucel T 60 malignant neoplasms 60 prostate carcinomas 60 myocardial infarction MI 60 5-FU/LV 60 systolic hypertension 60 HIPEC 60 carotid artery stenting 60 Lymph node 60 prognostic factors 60 retrospective cohort 60 testicular germ cell 60 Endometrial 60 biliary tract cancer 60 5FU 60 intra abdominal abscess 60 randomized multicenter trial 60 antiangiogenic agents 60 dose cytarabine 60 lymph node metastases 60 cutaneous melanoma 60 periprocedural 60 thyroidectomy 60 dacarbazine 60 ELACYT 60 CC genotype 60 TAVR 60 CTAP# Capsules 60 spiral computed tomography 60 thetreatment 60 flutamide 60 liver biopsies 60 miRview ™ squamous 60 relapsing multiple sclerosis 60 symptomatic VTE 60 MACCE 60 adriamycin 60 mucinous 60 hepatocellular cancer 60 precancerous cervical lesions 60 AVODART 60 pre operatively 60 carotid endarterectomy CEA 60 undetectable HBV DNA 60 definite stent thrombosis 60 placebo controlled clinical 60 invasive ductal 60 octreotide LAR 60 grade cervical dysplasia 60 anthracycline therapy 60 recurrent myocardial infarction 60 minimally symptomatic 60 nonoperative treatment 60 univariate analyzes 60 malignant neoplasm 60 GnRH agonists 60 allogeneic HSCT 60 pleural mesothelioma 60 deCODE BreastCancer TM 60 metastatic lung cancer 60 grade glioma 60 BRCA deficient 60 intraperitoneal chemotherapy 60 extracolonic findings 60 Sentinel node biopsy 60 hip resurfacing arthroplasty 60 cranial radiation 60 hormone receptor negative 60 reinfarction 60 FDG PET CT 60 Multivariate logistic regression 60 CYP#D# genotype 60 cinacalcet 60 plus prednisone 60 invasive carcinoma 60 Waldenstrom macroglobulinemia 60 cTnI 60 needle aspiration 60 stratifying patients 60 postoperative atrial fibrillation 60 psoriatic arthritis PsA 60 pertuzumab 60 contralateral breast cancer 60 bladder ovarian 60 liver metastases 60 APTIVUS r 60 XELOX 60 BCG refractory 60 BRCA mutation carriers 60 NSABP B 60 metastatic lymph nodes 60 pegylated liposomal doxorubicin 60 standard chemotherapy regimen 60 postintervention 60 serum prostate 60 Acute myeloid leukemia 60 colectomy 60 androgen deprivation therapy 60 salpingo oophorectomy 60 ASCT 60 unresectable locally advanced 60 prognostic indicator 60 TAXUS Express Stent 60 adenomatous 60 extrapleural pneumonectomy 60 cerebral angiography 60 cholangiocarcinoma 60 dimensional conformal radiation 60 Kaplan Meier 60 undergoing coronary artery 60 vertebral fracture 60 hypervascular tumors 60 androgen independent 60 carboplatin paclitaxel 60 bowel resection 60 BCIRG 60 ovarian lung 60 endometrial hyperplasia 60 KRAS status 60 MGUS 60 bone metastases 60 immunosuppressive regimens 60 nonoperative 60 EndoTAGTM 1 60 myeloablative 60 dose atorvastatin 60 chemosensitivity 60 leiomyomas 60 colorectal neoplasms 60 HBeAg negative 60 invasive coronary angiography 60 KRAS wild 60 erlotinib Tarceva ® 60 PITX2 60 diabetes mellitus DM 60 rectal carcinoma 60 axillary lymph node dissection 60 autologous transplants 60 Degarelix 60 gynecologic malignancy 60 intensity modulated 60 nomograms 60 PNH patients 60 oral anticoagulation 60 posttransplant 60 relapsed ALL 60 Fludarabine 60 chemo radiotherapy 60 noncancer 60 abnormal cytology 60 Naive Patients 60 unresectable stage 60 squamous cell carcinoma SCC 60 LHRH agonists 60 postoperative infection 60 lung metastases 60 pulmonary metastases 60 pancreatic colon 59 multimodality therapy 59 NSCLC 59 Stage IIB 59 lymphocytosis 59 bleomycin 59 allogeneic bone marrow 59 EGFR expressing 59 neuroendocrine cancers 59 gastric cardia 59 serum biomarker 59 Glioblastoma Multiforme 59 univariate 59 metastatic neuroendocrine tumors 59 coronary angiography 59 rectal cancers 59 sorafenib Nexavar ® 59 HER2 amplified 59 radiotherapy SBRT 59 CIMZIA TM certolizumab pegol 59 pulmonary dysfunction 59 Screening Trial 59 nonfatal MI 59 thrombotic complications 59 micrometastases 59 β blockers 59 EGFR TKI 59 urolithiasis 59 Adenomas 59 anastrazole 59 p = #.# [003] 59 haematologic 59 Idiopathic pulmonary fibrosis 59 chlorambucil 59 elevated LDH 59 CMV disease 59 depsipeptide 59 CLL SLL 59 inhibitor RG# 59 segmentectomy 59 PCNSL 59 anticoagulation therapy 59 tenecteplase 59 benign prostatic hyperplasia enlarged 59 hip BMD 59 axillary node 59 partial nephrectomy 59 alemtuzumab treated 59 excisional biopsy 59 flurpiridaz F 59 chemotherapy cisplatin 59 NCCTG N# 59 decompensated cirrhosis 59 bilateral orchiectomy 59 Recurrences 59 FOLFIRI 59 renal biopsy 59 ZACTIMA 59 liver histology 59 chemotherapy docetaxel 59 logistic regression analysis 59 CP CPPS 59 hepatocellular carcinoma HCC 59 pulmonary metastasis 59 coronary intervention 59 interstitial brachytherapy 59 rebleeding 59 OPCAB 59 CABG surgeries 59 ovarian malignancy 59 cranial irradiation 59 cervical intraepithelial neoplasia 59 Castration Resistant Prostate Cancer 59 Anthracycline 59 carotid endarterectomy 59 acute GvHD 59 TAXUS VI 59 severe neutropenia 59 platelet reactivity 59 PROSTVAC VF 59 allogeneic stem cell 59 myocardial necrosis 59 multidetector row 59 Xelox 59 micafungin 59 VELCADE melphalan 59 histologically proven 59 refractory multiple myeloma 59 carotid IMT 59 coinfected patients 59 immunomodulatory therapy 59 EGFR mutation positive 59 AVOREN 59 HDR brachytherapy 59 Alessandro Riva 59 demonstrated antitumor activity 59 low dose cytarabine 59 HSCT 59 lymphocytic leukemia 59 lymphoid malignancies 59 pelvic malignancies 59 thromboprophylaxis 59 renal transplantation 59 transarterial 59 glycated hemoglobin levels 59 CIN2 59 CBLC# 59 adenoma detection 59 gastroesophageal junction 59 squamous cell histology 59 K ras mutations 59 osteoporotic compression fractures 59 Androgen Deprivation Therapy 59 CaP 59 core needle biopsy 59 intensive lipid lowering 59 transitional cell carcinoma 59 placebo dexamethasone 59 sirolimus eluting stents 59 squamous intraepithelial lesions 59 gastrectomy 59 variceal hemorrhage 59 risk reducing salpingo 59 melphalan prednisone 59 intravenous bisphosphonates 59 EGFR expressing mCRC 59 genotypic resistance 59 RALP 59 intravesical infusion therapy 59 Ceplene/IL-2 59 curative therapy 59 FDG PET scans 59 HRPC 59 FUSILEV enhances 59 mg/m2 dose 59 multivariable adjusted 59 OnDose TM 59 FOLFOX6 59 neoplasias 59 post thrombotic syndrome 59 axillary nodes 59 valve implantation 59 intraductal 59 docetaxel Taxotere ® 59 sensitivity specificity 59 mycophenolate mofetil MMF 59 atypical ductal hyperplasia 59 chlamydial infection 59 dosage regimens 59 Critical Limb Ischemia CLI 59 thymectomy 59 OnDose 59 Venous thromboembolism 59 intestinal metaplasia 59 pretransplant 59 #Gy 59 XIENCE V PROMUS Stent 59 venous thromboembolic disease 59 pretest probability 59 interferon ribavirin 59 antiangiogenic agent 59 localized prostate 59 CT colonography CTC 59 Liver transplantation 59 differentiate squamous 59 macroalbuminuria 59 genitourinary cancers 59 Metastatic 59 oral deforolimus 59 acute coronary syndromes ACS 59 FOLFOX regimen 59 neurocognitive function 59 FDG PET scan 59 hematopoietic cancers 59 Carotid artery stenting 59 Aflibercept 59 palliation 59 receiving highly emetogenic 59 relapsed Hodgkin lymphoma 59 stage IIIb 59 prior chemotherapy regimens 59 Stage IIIb 59 hypofractionated 59 estimated glomerular filtration 59 thrombophilia 59 total abdominal hysterectomy 59 invasive carcinomas 59 urothelial bladder cancer 59 metastatic cancer 59 carcinoid tumors 59 paclitaxel cisplatin 59 ischemic lesions 59 CCyR 59 brain metastases 59 EGFR mutation status 59 sirolimus stent 59 SCCHN 59 chronic periodontitis 59 helical CT 59 bone metastasis 59 noninvasive outpatient 59 coronary revascularisation 59 pancreatic NET 59 aromatase inhibitors AIs 59 lipid lowering agents 59 haematological cancers 59 multivariate logistic regression 59 hepatocellular carcinoma liver 59 recurrent DVT 59 Folfox 59 GP IIb IIIa inhibitors 59 neoadjuvant chemoradiotherapy 59 resectable pancreatic cancer 59 chronic thromboembolic pulmonary 59 Phase III randomized controlled 59 adnexal masses 59 oblimersen 59 cerebral microbleeds 59 Hazard Ratio 59 subtrochanteric 59 IV bisphosphonates 59 miRview mets 59 eTag assays 59 cisplatin gemcitabine 59 laparoscopically assisted 59 lenalidomide Revlimid R 59 ADPKD 59 femoral neck fracture 59 recurrent ovarian cancer 58 intravenous diuretics 58 Malignant Melanoma 58 intensity modulated radiotherapy IMRT 58 Coronary artery bypass graft 58 renal artery stenosis 58 multivessel disease 58 PITX2 methylation 58 serum testosterone 58 donor nephrectomy 58 Platinol ® 58 dysglycemia 58 urodynamic 58 Invasive Breast Cancer 58 induce remission 58 renal carcinoma 58 paricalcitol 58 deep venous thromboses 58 colonic polyps 58 confidence intervals CIs 58 CIMZIA ™ 58 Phase #b/#a clinical 58 tamoxifen Nolvadex ® 58 preserved LVEF 58 methotrexate monotherapy 58 intra arterial chemotherapy 58 lumbar disc herniation 58 Carotid Revascularization Endarterectomy vs. 58 X ray angiography 58 faulty BRCA2 gene 58 HER2 + 58 thyroglobulin 58 prostate biopsies 58 FIRMAGON 58 distal colon cancer 58 dasatinib Sprycel ® 58 RE LY ® 58 microsatellite instability 58 Prostate Lung Colorectal 58 ventricular tachyarrhythmia 58 recurrent glioma 58 lenalidomide dexamethasone 58 radiofrequency ablation RFA 58 hormone receptor positive 58 complete cytogenetic response 58 urine dipstick